Please assess the completion status of the following clinical trial:

Trial Title: KIDCARE (Kawasaki Disease Comparative Effectiveness Trial)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Eligible subjects will be as follows:~  1. 4 weeks to 17 years of age,~ 2. fulfill the American Heart Association case definition for complete or incomplete KD,~ 3. have had fever (T ≥38°C) for 3 to 10 days prior to initial IVIG treatment,~ 4. have fever (T ≥38°C orally or rectally) between 36 hours and 7 days after end of the first IVIG infusion without other likely cause~Exclusion Criteria:~1. Patient treated with infliximab or steroids for present illness (pts who received oral steroids as outpatients prior to KD diagnosis but who otherwise qualify for the study will not be excluded)~2. Known prior infection with tuberculosis, coccidiomycosis, or histoplasmosis.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- IVIG (Type: ACTIVE_COMPARATOR): Patient will be randomly assigned to receive a second IVIG infusion: 2 g/kg IV over 8-10 hours single infusion
- Infliximab (Type: ACTIVE_COMPARATOR): Patient will be randomly assigned to receive Infliximab 10 mg/kg IV over 2 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).